Roche PPAR Development Delayed By FDA-Required Carcinogenicity Tests
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies for Roche's insulin sensitizer R483 will be postponed pending completion of FDA-required two-year carcinogenicity testing